ReviewNeuroRx : the journal of the American Society for Experimental NeuroTherapeutics2004
Clinical trials for cytoprotection in stroke.
Review in NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 122 citations in OpenAlex.
- Pilot Feasibility and Safety Study of Hydrogen Gas Inhalation in Locally Advanced Head and Neck Cancer Patients.OncoTargets and therapy · 2024Trial
- Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial.Journal of medicine and lifeTrial
- Cerebrolysin adjuvant treatment in Broca's aphasics following first acute ischemic stroke of the left middle cerebral artery.Journal of medicine and lifeTrial
- Article
- Citicoline: pharmacological and clinical review, 2022 update.Revista de neurologia · 2022Review
- Cytoprotective Activity of Newly Synthesized 3-(Arylmethylamino)-6-Methyl-4-Phenylpyridin-2(1Molecules (Basel, Switzerland) · 2022Article
- Bridging the Gap Between Diabetes and Stroke in Search of High Clinical Relevance Therapeutic Targets.Neuromolecular medicine · 2019Review
- Comparison of ion channel inhibitor combinations for limiting secondary degeneration following partial optic nerve transection.Experimental brain research · 2019Article
- Treatment duration affects cytoprotective efficacy of positive allosteric modulation of α7 nAChRs after focal ischemia in rats.Pharmacological research · 2018Article
- Targeted temperature management in neurological intensive care unit.World journal of methodology · 2017Review
- A critical role for interferon regulatory factor 9 in cerebral ischemic stroke.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2014Article
- The science of cerebral ischemia and the quest for neuroprotection: navigating past failure to future success.Journal of neurosurgery · 2013Review
- Towards a roadmap in brain protection and recovery.Journal of cellular and molecular medicine · 2012Review
- Hydrogen-rich saline protects spermatogenesis and hematopoiesis in irradiated BALB/c mice.Medical science monitor : international medical journal of experimental and clinical research · 2012Article
- In vivo imaging of brain ischemia using an oxygen-dependent degradative fusion protein probe.PloS one · 2012Article
- Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2011Article
- C-terminus of heat shock cognate 70 interacting protein increases following stroke and impairs survival against acute oxidative stress.Antioxidants & redox signaling · 2011Article
- A possible prevention strategy of radiation pneumonitis: combine radiotherapy with aerosol inhalation of hydrogen-rich solution.Medical science monitor : international medical journal of experimental and clinical research · 2011Article
- Experimental and clinical use of therapeutic hypothermia for ischemic stroke: opportunities and limitations.Stroke research and treatment · 2011Article
- Hydrogen gas reduced acute hyperglycemia-enhanced hemorrhagic transformation in a focal ischemia rat model.Neuroscience · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
To date, many cytoprotective drugs have reached the stage of pivotal phase 3 efficacy trials in acute stroke patients. (Table 1) Unfortunately, throughout the neuroprotective literature, the phrase "failure to demonstrate efficacy" prevails as a common thread among the many neutral or negative trials, despite the largely encouraging results encountered in preclinical studies. The reasons for this discrepancy are multiple, and have been discussed by Dr. Zivin in his review. Many of the recent trials have addressed deficiencies of the previous ones with more rigorous trial design, including more specific patient selection criteria (ensure homogeneity of stroke location and severity), stratified randomization algorithms (time-to-treat), narrowed therapeutic time-window and pharmacokinetic monitoring. Current trials have also incorporated biologic surrogate markers of toxicity and outcome such as drug levels and neuroimaging. Lastly, multi-modal therapies and coupled cytoprotection/reperfusion strategies are being investigated to optimize tissue salvage. This review will focus on individual therapeutic strategies and we will emphasize what we have learned from these trials both in terms of trial design and the biologic effect (or lack thereof) of these agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.